Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells.
### Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
### Adult Dosing
* **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. A second 8-week course may be considered for patients who have not healed.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally twice daily. Doses may be titrated up to 240 mg daily. Doses > 80 mg daily should be administered in divided doses.
### Pediatric Dosing
* **Erosive Esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **GERD (5 years and older):** 20 mg orally once daily for up to 8 weeks. Dosing for children younger than 5 years is not well-established.
### Dose Adjustments
No dose adjustment is generally required for patients with hepatic or renal impairment.
### Contraindications
* Known hypersensitivity to pantoprazole or any other benzimidazole derivatives.
### Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* **Serious:**
* Long-term use may increase the risk of *Clostridium difficile*-associated diarrhea.
* Long-term use may be associated with an increased risk of bone fractures (hip, wrist, spine).
* May cause hypomagnesemia, particularly with prolonged use (>1 year), which can be serious and may lead to symptoms like muscle cramps, seizures, or arrhythmias.
* Vitamin B12 deficiency can occur with prolonged use.
* Acute interstitial nephritis.
### Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, and mycophenolate mofetil. Pantoprazole can decrease their absorption.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution with drugs like clopidogrel, as effects may be reduced (though clinical significance is debated).
### Monitoring
* Monitor for signs and symptoms of hypomagnesemia and vitamin B12 deficiency with prolonged use.
* Consider bone mineral density assessment in patients at risk for osteoporosis.
* Assess for *C. difficile* infection if diarrhea develops.
### Clinical Pearls
* Administer pantoprazole at least 1 hour before a meal.
* For delayed-release formulations, do not crush or chew tablets; swallow whole.
* IV formulation is available for patients unable to take oral medication. Dosing is typically 40 mg once daily.
* Consider the potential for drug interactions and long-term risks before initiating therapy, especially for non-FDA-approved indications or prolonged duration.
***
**Disclaimer:** This information is intended for clinical use and does not replace the official prescribing information. Always verify current product information and consult with the relevant drug compendium or manufacturer's guidelines before prescribing or dispensing.
